

המינהל לטכנולוגיות רפואיות ותשתיות אנף הרוקחות | המכון לביקורת ותקנים של חומרי רפואה

The Institute for Standardization and Control of Pharmaceuticals

Certificate No: GMP 95/14

CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER

Part 1

Issued following an inspection in accordance with the requirements of Good Manufacturing Practice, of the Israeli laws and regulations (Pharmacist Regulations [Good Manufacturing Practice for Medicinal Products] 2008)

and

Issued under the provisions of the Conformity Assessment and Acceptance of Industrial Products (CAA) Agreement between the European Union and Israel

The competent authority of Israel confirms the following:

The manufacturer SOREQ NRC, Radiopharmautial Division / Isorad Ltd.

Site address Soreq Nuclear Research Center, Yavne, P.O.B. 239, 8110102, Israel

Has been inspected under the Israeli inspection programme, in connection with manufacturing authorization no. **MIA 95**, in accordance with the above mentioned laws and regulations

From the knowledge gained during inspection of this manufacturer, the latest of which were conducted on **4-8 February 2024**, it is considered that it complies with the Good Manufacturing Practice requirements referred to in the Conformity Assessment and Acceptance of Industrial Products (CAA) Agreement between the European Union and Israel and the above mentioned Israeli laws and regulations (*).

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than **three years** have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field.

This certificate is valid only when presented with all pages and both Parts 1 and 2.

The authenticity of this certificate may be verified in EudraGMP. If it does not appear, please contact the issuing authority.

(*) these requirements fulfill the GMP recommendations of WHO

11 March 2024

GMP 95/14

light Cani

page 1 of 3



המינהל לטכנולוגיות רפואיות ותשתיות

אגף הבוקחות | <mark>המכון לביקורת ותקנים של חומרי רפואה</mark> The Institute for Standardization and Control of Pharmaceuticals

Part 2

HUMAN MEDICINAL PRODUCTS

1. MANUFACTURING OPERATIONS - MEDICINAL PRODUCTS

- 1.1 Sterile products
 - 1.1.2 Terminally sterilized
 - 1.1.2.5 Other terminally sterilized prepared products : *Radioactive products*
 - 1.1.3 Batch certification
- 1.5 Packaging
 - 1.5.1 Primary packing
 - 1.5.1.10 Radionuclide generators
 - 1.5.2 Secondary packing
- 1.6 Quality control testing
 - 1.6.1 Microbiological: sterility
 - 1.6.2 Microbiological: non-sterility
 - 1.6.3 Chemical/Physical
 - 1.6.4 Biological (endotoxins)

2. IMPORTATION OF MEDICINAL PRODUCTS

- 2.2 Batch certification of imported medicinal products
 - 2.2.1 Sterile Products
 - 2.2.1.1 Aseptically prepared
 - 2.2.1.2 Terminally sterilized
- 2.3 Other importation activities
 - 2.3.1 Site of physical importation
 - 2.3.4 Other: Radionuclide generators

lichal Cani

11 March 2024

GMP 95/14

page 2 of 3



המינהל לטכנולוגיות רפואיות ותשתיות אגף הרוקחות | המכון לביקורת ותקנים של חומרי רפואה

The Institute for Standardization and Control of Pharmaceuticals

Any restrictions or clarifying remarks related to the scope of this certificate:

1.2.1.5 The plant manufactures three Radioactive products:

Technetium Tc-99M Generator, Thallium Chloride Tl-201, Gallium (Ga-67) Citrate

light Cani

Name and signature of the authorized person of the Competent Authority of Israel:

Michael Carmi, Pharmacist, GMP Inspector

Email: michael.carmi@moh.gov.il

Phone: office 972 -2-6551795, cell 972-50-6242452

11 March 2024

GMP 95/14

page 3 of 3